At the sleep research meeting in San Antonio this year, there were signs of an impending pharmaceutical arms race in the realm of narcolepsy.
The big fish in a small pond, Jazz Pharmaceuticals, was preparing to market its recently FDA-approved medication: Sunosi/solriamfetol. Startup Harmony Biosciences was close behind with pitolisant, already approved in Europe. On the horizon are experimental drugs designed to more precisely target the neuropeptide deficiency in people with classic narcolepsy type 1 Read more
Quyyumi’s team looked at progenitor cells, which circulate in the blood and are attracted to sites of injury. In a group of 356 patients with stable coronary artery disease, the researchers saw that some (31 percent) had “ExMI” – exercise-mediated myocardial ischemia. That means impairments in blood flow were visible via cardiac imaging under the stress of exercise. This is a relatively mild impairment; participants did not report chest pain. This paper emerges from the MIPS (Mental Stress Ischemia Prognosis) study, 2011-2014.
The ambulance-progenitor cell analogy isn’t perfect; exercise, generally a good thing, increases progenitor cell levels in the blood, says co-first author and cardiology fellow Muhammad Hammadah. The study supports the idea that patients with coronary artery disease may benefit from cardiac rehab programs, which drive the progenitor cells into the ischemic tissue, so they can contribute into vascular repair and regeneration. Read more
In this case, Yuâ€™s team wasÂ using parathyroid hormone (PTH), which is an FDA-approved treatment for osteoporosis. They administered it, beginning one hour after loss of blood flow, in a mouse model of ischemic stroke. They foundÂ that daily treatment with PTH spurs production of endogenousÂ regenerative factors in the stroke-affected area of the brain. They observed both increased new neuron formation and sensorimotor functional recovery. However, PTH does not pass through the blood-brain barrier and does not change the size of the stroke-affected area, the researchers found.
The conclusion of the paper hints at their next steps:
As this is the first report on this PTH therapy for ischemic stroke for the demonstration of the efficacy and feasibility, PTH treatment was initiated at 1 hr after stroke followed by repeated administrations for 6 days. We expect that even more delayed treatment of PTH, e.g. several hrs after stroke, can be beneficial in promoting chronic angiogenesis and other tissue repair processes. This possibility, however, remains to be further evaluated in a more translational investigation.
Go check out the article on the EmoryÂ Office of Technology Transfer’s site on Jacques Galipeau and the artificial chimeric immune stimulators he’s invented. He and his colleagues take one immune regulatory molecule, GM-CSF, and stick it onto others, creating a series of potent immune stimulants he calls “fusokines.” According to Galipeau, one of them turns antibody-producing B cells into The Hulk. Another is like a five hour energy drink.
These super-stimulants may be especially ray ban outlet effective in the realm of cancer, where the immune system is not responding to a stealthy threat.Â But in dealing with autoimmune diseases such as multiple sclerosis or inflammatory bowel disease, it is more necessary to rein in over-enthusiastic immune cells. Galipeau has devised a fusokine that apparently reprograms cells into being more orderly.
Two presentations on Emory research at last week’s AIDS Vaccine 2010 conference concerned adjuvants. These are substances that act as amplifiers, stimulating the immune system while keeping its focus on the specific components of a vaccine.
Charlie Janeway (1943-2003)
Immunologist Charlie Janeway once described adjuvants as immunology’s “dirty little secret,” because for a long time scientists did not know how they worked. Some adjuvants can sound irritating and nasty, such as alum and oil emulsion. Alum is the only vaccine adjuvant now licensed for human clinical use in the US. Over the last few years, scientists have learned that adjuvants rev up what is now known as the “innate immune system,” so that the body knows that the vaccine is something foreign and dangerous.
Rama Rao Amara, a vaccine researcher at Emory Vaccine Center and Yerkes National Primate Research Center, and Harriet Robinson, former head of microbiology and immunology at Yerkes and now chief scientific officer at the firm GeoVax, both described extra ingredients for the DNA/MVA vaccine that Robinson designed while at Yerkes in collaboration with NIH researchers.
Peripheral artery disease affects millions of people in the United States. It’s basically hardening of the arteries (atherosclerosis) leading to problems with getting enough blood to the limbs. Symptoms of severe PAD include leg pain that doesn’t go away once exertion stops and wounds that heal slowly or not at all.
Lifestyle changes, medication and surgery can address some cases of PAD, but often the disease is not recognized until it has advanced considerably. At Emory, cardiologist Arshed Quyyumi has been exploring whether a patient’s own bone marrow cells can repair the arteries in his or her limbs.